CDK 4/6 Inhibitors in HR+/HER2- Breast Cancer – Northfield, MN
This program will review the use of CDK 4/6 inhibitors in the treatment of HR+/HER2-negative breast cancer and the management of treatment-related adverse events.
This program will review the use of CDK 4/6 inhibitors in the treatment of HR+/HER2-negative breast cancer and the management of treatment-related adverse events.
This live activity is focused on treatment strategies for patients with hepatocellular carcinoma (HCC).
This activity is primarily designed for U.S.-based members of multidisciplinary teams involved in the management of patients with Axial Spondyloarthritis.